ViaCyte
San Diego
About ViaCyte
ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $235.5M
- Funding stage: M&A
- Last round: Series D (Apr 2021)
- Website: viacyte.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Diabetes, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/viacyte-82979 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.